-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $900

Benzinga·12/19/2025 12:48:32
語音播報
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price target from $540 to $900.